

# Steven Stone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/771542/publications.pdf>

Version: 2024-02-01

44  
papers

7,529  
citations

567281

15  
h-index

454955

30  
g-index

44  
all docs

44  
docs citations

44  
times ranked

7983  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 366.e19-366.e28.	1.6	1
2	Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. <i>European Urology</i> , 2021, 79, 141-149.	1.9	4
3	Cell cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone. <i>Prostate</i> , 2021, 81, 261-267.	2.3	3
4	Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 195-195.	1.6	0
5	Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate- and high-risk prostate cancer overall, and in those who also received salvage radiotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 247-247.	1.6	0
6	Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 296-304.e3.	1.9	6
7	Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy. <i>Cancer Reports</i> , 2021, , e1535.	1.4	2
8	The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.8	9
9	Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 102-107.	3.9	26
10	Biopsy Cell Cycle Proliferation Score Predicts Adverse Surgical Pathology in Localized Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 657-660.	1.9	10
11	Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 346-346.	1.6	1
12	Ability of cell-cycle progression score to predict risk for progression to metastatic disease and disease-specific mortality in prostate cancer patients after prostatectomy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5524-5524.	1.6	0
13	Renal biopsy cell cycle proliferation (CCP) score to predict adverse surgical pathology in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 747-747.	1.6	0
14	Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score. <i>Personalized Medicine</i> , 2019, 16, 491-499.	1.5	9
15	Extracapsular extension on MRI indicates a more aggressive cell cycle progression genotype of prostate cancer. <i>Abdominal Radiology</i> , 2019, 44, 2864-2873.	2.1	8
16	Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer. <i>European Urology</i> , 2019, 75, 515-522.	1.9	22
17	Outcomes of men with prostate cancer managed with active surveillance and tested with clinical cell-cycle risk score.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16566-e16566.	1.6	0
18	Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate and high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16575-e16575.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Cell cycle progression score differentiates indolent from aggressive prostate cancer in men diagnosed by TURP.. Journal of Clinical Oncology, 2019, 37, e16560-e16560.	1.6	0
20	Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy. World Journal of Urology, 2018, 36, 1495-1500.	2.2	25
21	Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 310.e7-310.e13.	1.6	19
22	A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. European Urology, 2018, 73, 763-769.	1.9	63
23	Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance. BJU International, 2017, 120, 808-814.	2.5	48
24	Patient NCCN risk classification based on combined clinical cell cycle risk (CCR) score.. Journal of Clinical Oncology, 2017, 35, 249-249.	1.6	1
25	Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression.. Journal of Clinical Oncology, 2017, 35, e16566-e16566.	1.6	0
26	Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. Cancer Biomarkers, 2016, 17, 83-88.	1.7	15
27	Prognostic utility of a multi-gene signature (the cell cycle proliferation score) in patients with renal cell carcinoma (RCC) after radical nephrectomy.. Journal of Clinical Oncology, 2016, 34, 555-555.	1.6	0
28	Cell cycle progression score predicts metastatic progression of clear cell renal cell carcinoma after resection. Cancer Biomarkers, 2015, 15, 861-867.	1.7	17
29	Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer.. Journal of Clinical Oncology, 2015, 33, e16040-e16040.	1.6	1
30	Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing.. Journal of Clinical Oncology, 2015, 33, 64-64.	1.6	2
31	Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing.. Journal of Clinical Oncology, 2015, 33, 5033-5033.	1.6	0
32	In Reply to Berlin etÂal. International Journal of Radiation Oncology Biology Physics, 2014, 88, 240-241.	0.8	0
33	Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy. Journal of Urology, 2014, 192, 409-414.	0.4	180
34	Predicting radical prostatectomy outcome: Cell cycle progression (CCP) score compared with primary Gleason grade among men with clinical Gleason less than 7 who are upgraded to Gleason 7.. Journal of Clinical Oncology, 2014, 32, 13-13.	1.6	2
35	CCP score and risk stratification for prostate cancer patients at biopsy.. Journal of Clinical Oncology, 2014, 32, 47-47.	1.6	4
36	Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy.. Journal of Clinical Oncology, 2014, 32, 17-17.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Cell cycle progression score to predict metastatic progression of clear cell renal cell carcinoma after resection.. Journal of Clinical Oncology, 2014, 32, 442-442.	1.6	0
38	Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort.. Journal of Clinical Oncology, 2014, 32, 5059-5059.	1.6	0
39	Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort. Journal of Clinical Oncology, 2013, 31, 1428-1434.	1.6	323
40	Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncology, The, 2011, 12, 245-255.	10.7	668
41	TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition. Human Molecular Genetics, 2006, 15, 2709-2720.	2.9	129
42	A Major Predisposition Locus for Severe Obesity, at 4p15-p14. American Journal of Human Genetics, 2002, 70, 1459-1468.	6.2	133
43	Linkage of body mass index to chromosome 20 in Utah pedigrees. Human Genetics, 2001, 109, 279-285.	3.8	51
44	A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene <i>BRCA1</i>. Science, 1994, 266, 66-71.	12.6	5,747